Press release
Investigation announced for Investors in shares of Curis, Inc. (NASDAQ: CRIS)
An investigation on behalf of investors in Curis, Inc. (NASDAQ: CRIS) shares over potential wrongdoing at Curis, Inc.
Investors who purchased shares of Curis, Inc. (NASDAQ: CRIS) and NASDAQ: CRIS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Curis, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Lexington, MA based Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Curis, Inc. reported that its annual Total Revenue rose from $10 million in 2019 to $10.83 million in 2020, and that its Net Loss declined from $32.14 million in 2019 to $29.9 million in 2020.
On June 11, 2021, Curis, Inc. issued a press release "announc[ing] updated data from its ongoing Phase 1/2 open-label, single arm, dose escalation and expansion trial of CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA). Specifically, Curis stated that it had "concluded 300mg BID is the optimal dose to take into Phase 2 studies" after the 500 mg and 400 mg versions of the drug showed dose-limited toxicities. Shares of Curis, Inc. (NASDAQ: CRIS) declined from $15.60 per share on June 8, 2021 to as low as $7.11 per share on June 22, 2021.
Those who purchased shares of Curis, Inc. (NASDAQ: CRIS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Curis, Inc. (NASDAQ: CRIS) here
News-ID: 2356882 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Curis
Myelodysplastic Syndrome Clinical Trials, Companies, Therapeutic Assessment, The …
DelveInsight's, "Myelodysplastic Syndrome - Pipeline Insight, 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 120 key companies are actively engaged…
Hedgehog Pathway Inhibitors Market Is Booming So Rapidly | Pfizer, Roche, Curis
The latest study released on the Global Hedgehog Pathway Inhibitors Market by USD Analytics Market evaluates market size, trend, and forecast to 2032. The Hedgehog Pathway Inhibitors market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the…
Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinical Trials Development an …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome…
Investigation announced for Investors in shares of Curis, Inc. (NASDAQ: CRIS)
An investigation was announced concerning possible violations of securities laws by Curis, Inc. in connection with certain financial statements.
Investors who purchased shares of Curis, Inc. (NASDAQ: CRIS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Curis, Inc. regarding its business, its prospects and its operations were materially…
Global Histone Deacetylase 1 Market 2020 Key Factors and Emerging Opportunities …
A recently published report by MarketsandResearch.biz with the title Global Histone Deacetylase 1 Market 2020 gives the point by point coverage of the industry with its major market trends. The report covers the market landscape and its evolution predictions during the forecast period from 2020 to 2025. The report provides research on market size, the development condition, advancement pattern, activity situation, and future advancement trends of the global Histone Deacetylase…
Curis - Cancer Drugs Clinical Pipeline Insight
“Curis - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Curis. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “7” cancer drugs in clinical pipeline. There is 1 cancer drug by Curis which are commercially available in the market.
The report includes all the relevant information…
